Correlation of p53 gene mutation and expression of P53 protein in cholangiocarcinoma

World Journal of Gastroenterology

Volumn 12, Issue 29, 2006, Pages 4706-4709

  Liu, Xiao Fang ^a   Zhang, Hao ^b   Zhu, Shi Guang ^a   Zhou, Xian Ting ^a   Su, Hai Long ^a   Xu, Zheng ^a   Li, Shao Jun ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; DNA sequence; Mutation; p53 gene

Indexed keywords

DNA; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; EXON; FEMALE; FROZEN SECTION; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PROGNOSIS; SEQUENCE ANALYSIS; TISSUE DIFFERENTIATION;

EID: 33747727606     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i29.4706     Document Type: Article

References (28)

1. Forslund A, Kressner U, Lonnroth C, Andersson M, Lindmark G, Lundholm K. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH. Int J Oncol 2002; 21: 409-415
2. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002; 4: 70-76
3. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat 2003; 21: 201-216
4. Caldeira S, Filotico R, Accardi R, Zehbe I, Franceschi S, Tommasino M. p53 mutations are common in human papillomavirus type 38-positive non-melanoma skin cancers. Cancer Lett 2004; 209: 119-124
5. Baroni TE, Wang T, Qian H, Dearth LR, Truong LN, Zeng J, Denes AE, Chen SW, Brachmann RK. A global suppressor motif for p53 cancer mutants. Proc Natl Acad Sci USA 2004; 101: 4930-4935
6. Lin JT, Wang JS, Jiann BP, Yu CC, Tsai JY, Huang JK, Wu TT. Correlation of p53 protein accumulation and Bcl-2 overexpression with histopathological features in prostatic cancer. J Formos Med Assoc 2005; 104: 864-867
7. El Far MA, Atwa MA, Yahya RS, El Basuni MA. Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt, Clin Chem Lab Med 2006; 44: 653-656
8. Saetta AA. K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer. J Surg Oncol 2006; 93: 644-649
9. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 2006; 12: 192-198
10. Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 2004; 61: 822-842
11. Mir MM, Dar NA, Gochhait S, Zargar SA, Ahangar AG, Bamezai RN. p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int J Cancer 2005; 116: 62-68
12. Moreno M, Pimentel F, Gazdar AF, Wistuba II, Miquel JF. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma. Ann Hepatol 2005; 4: 192-199
13. Wang X, Zhang J, Chen J. Result of p53, ki-67 protein expression in cholangiocarcinoma with in situ hybridization and immunohistochemistry methods. Zhongguo Yixue Kexueyuan Xuebao 2000; 22: 57-60
14. Ahrendt SA, Rashid A, Chow JT, Eisenberger CF, Pitt HA, Sidransky D. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 2000; 7: 426-431
15. Horie S, Endo K, Kawasaki H, Terada T. Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features. Virchows Arch 2000; 437: 25-30
16. Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, Imaoka S, Tsujimoto M, Matsuura N. Expression and clinical significance of the G1-S modulators in intrahepatic cholangiocellular carcinoma. Oncology 2001; 60: 242-251
17. Attallah AM, Abdel-Aziz MM, El-Sayed AM, Tabll AA. Detection of serum p53 protein in patients with different gastrointestinal cancers. Cancer Detect Prev 2003; 27: 127-131
18. Jan YY, Yeh CN, Yeh TS, Chen TC. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 2005; 11: 17, 79-1784
19. Liu XF, Zhou XT, Zou SQ. An analysis of 680 cases of cholangiocarcinoma from 8 hospitals. Hepatobiliary Pancreat Dis Int 2005; 4: 585-588
20. Reddy SB, Patel T. Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 2006; 8: 30-37
21. Singh P, Patel T. Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol 2006; 22: 294-299
22. Mansfield SD, Barakat O, Charnley RM, Jaques BC, O'Suilleabhain CB, Atherton PJ, Manas D. Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome. World J Gastroenterol 2005; 11: 7625-7630
23. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 33-42
24. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314
25. Sakata J, Shirai Y, Wakai T, Nomura T, Sakata E, Hatakeyama K. Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma. World J Gastroenterol 2005; 11: 7024-7027
26. Hubert C, Sempoux C, Berquin A, Deprez P, Jamar F, Gigot JF. Bile duct carcinoid tumors: an uncommon disease but with a good prognosis? Hepatogastroenterology 2005; 52: 1042-1047
27. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003; 21: 217-228
28. Khan SA, Taylor-Robinson SD, Carmichael PL, Habib N, Lemoine NR, Thomas HC. Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. Int J Oncol 2006; 28: 1269-1277